CRINETICS PHARMACEUTICALS IN (CRNX)
US22663K1079 - Common Stock
| MRQ (2024-3-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 395.92M | 54.90M | 32.70M | 200.70M | 93.10M | |||
| Marketable Securities | 505.04M | 503.66M | 301.80M | 133.00M | 77.80M | |||
| Receivables | 8.56M | 9.10M | 2.30M | 1.50M | 1.80M | |||
| Other Current Assets | 7.71M | 6.50M | 8.50M | 9.50M | 4.80M | |||
| Total Current Assets | 917.23M | 574.15M | 345.20M | 344.70M | 177.50M | |||
| Non-Current Assets | ||||||||
| PPE Net | 57.63M | 57.43M | 5.00M | 4.70M | 5.40M | |||
| Investments And Advances | 0.00 | 470.00K | 0.00 | 1.00M | N/A | |||
| Other Non-Current Assets | 3.30M | 3.30M | 2.00M | 600.00K | 500.00K | |||
| Total Non-Current Assets | 60.92M | 61.20M | 7.00M | 6.30M | 5.90M | |||
| TOTAL ASSETS | 978.15M | 635.35M | 352.20M | 351.00M | 183.40M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | N/A | N/A | N/A | N/A | N/A | |||
| Accrued Expenses | 38.55M | 35.34M | 18.60M | 7.50M | 4.90M | |||
| Accounts Payable | 10.76M | 6.55M | 6.90M | 8.50M | 5.60M | |||
| Other Current Liabilities | 2.46M | 2.06M | 2.20M | N/A | N/A | |||
| Total Current Liabilities | 51.77M | 43.94M | 27.70M | 16.00M | 10.50M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Other Non-Current Liabilities | 51.45M | 52.30M | 8.10M | 3.10M | 4.00M | |||
| Total Non-Current Liabilities | 51.45M | 52.30M | 8.10M | 3.10M | 4.00M | |||
| TOTAL LIABILITIES | 103.22M | 96.25M | 35.80M | 19.10M | 14.50M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -720.63M | -653.70M | -439.20M | -275.30M | -167.60M | |||
| Additional Paid In Capital | N/A | N/A | N/A | N/A | N/A | |||
| Common Shares | 1.60B | 1.19B | 759.40M | 607.60M | 336.50M | |||
| Other Shareholders' Equity | 150.00K | 977.00K | -3.90M | -400.00K | 0.00 | |||
| Shares Outstanding | 78.54M | 68.17M | 53.90M | 47.60M | 33.00M | |||
| Tangible Book Value per Share | 11.14 | 7.91 | 5.87 | 6.97 | 5.12 | |||
| Total Shareholders' Equity | 874.93M | 539.11M | 316.30M | 331.90M | 168.90M | |||
| TOTAL LIABILITIES AND EQUITY | 978.15M | 635.35M | 352.20M | 351.00M | 183.40M | |||
| Statistics | ||||||||
| Debt/Equity | N/A | N/A | N/A | N/A | N/A | |||
| Current Ratio | 17.72 | 13.07 | 12.46 | 21.54 | 16.90 | |||
| Return On Assets (ROA) | -24.07% | -33.77% | -46.54% | -30.67% | -40.25% | |||
| Return On Equity (ROE) | -26.91% | -39.79% | -51.82% | -32.43% | -43.70% | |||
All data in USD